Efficacy of hydroxychloroquine as a potential antidiabetic drug

Mithun Kumar D.*, Laxminarayana Kamath, Narayana Reddy S.

ABSTRACT

Background: India is the world’s diabetic capital. Oral antidiabetic therapy is still incomplete. Prior studies have shown that hydroxychloroquine (HCQ), a commonly used antimalarial, anti-rheumatic drug reduces the risk of developing diabetes mellitus. It probably acts by decreasing insulin metabolism- a novel mechanism of action.

Methods: A systematic search was done in MEDLINE database with key words ‘Type 2 Diabetes Mellitus’, ‘Hydroxychloroquine’. Articles assessing the antidiabetic efficacy of hydroxychloroquine were reviewed and their results summarized.

Results: With extensive literature search, we found out three RCTs and four Cohort studies assessing the efficacy of HCQ on glycaemic markers in patients with type 2 diabetes mellitus. Two randomized controlled trials done by Gerstein H C et al, Pareek A et al, comparing hydroxychloroquine with established antidiabetic drugs showed that there is significant reduction in glycaemic parameters with comparable similarity in both the groups (HbA1c: -0.91%±0.4%). Solomon et al in their study on patients with RA concluded that HCQ improved insulin sensitivity. Two cohort studies by Chen Y M et al and Wasko MCM et al respectively showed reduced incidence of diabetes mellitus in Systemic lupus erythematosus (Hazard ratio=0.26) and rheumatologic disease (relative risk=0.23) patients who received hydroxychloroquine. In a cohort study by Rekedal LR et al, HCQ reduced HbA1c by 0.66% compared to baseline in patients with RA. These studies also showed that hydroxychloroquine has favourable effect on lipid profile and good tolerability.

Conclusions: Hydroxychloroquine has a potential to enter antidiabetic armamentarium due to its efficacy and low toxicity profile. More studies are required to confirm this.

Keywords: Antidiabetic drugs, Hydroxychloroquine, Lipid profile, Novel

INTRODUCTION

Diabetes mellitus (DM) refers to “a group of common metabolic disorders that share the phenotype of hyperglycemia. Type 1 DM is the result of complete or near-total insulin deficiency. Type 2 DM is a heterogeneous group of disorders characterized by variable degrees of insulin resistance, impaired insulin secretion, and increased glucose production.” Globally there were 422 million types 2 diabetes in 2014 out of which 69.2 million were from India which is projected to be 109 million by 2035. These figures translate to a prevalence of 8.6% in Southeast Asia. Oral antidiabetic drugs metformin and sulfonylurea is the established initial therapy for type 2 DM. However the UKPDS study showed that sulfonylureas and metformin lose their efficacy with time. About 50% of the patients on sulfonylurea or metformin monotherapy require additional agents to maintain glycaemic control after 3 years. Even though thiazolidinediones, meglitinides, gliptins can be added to the therapeutic regimen of patients with secondary failure to initial therapy, they have limitations. Researchers are constantly in search of a new anti-diabetic drug which is safe as well as efficacious.

HCQ is a synthetic antimalarial drug commonly used in the treatment of autoimmune diseases like RA and SLE. HCQ use is associated with reduced DM incidence, reduction in HbA1c, blood glucose levels and improved
lipid profile. HCQ most likely acts by reducing the lysosomal degradation of internalised insulin-insulin receptor complex. This is a novel mechanism of action in contrast to insulin secretagogue or insulin sensitizer action of other antidiabetic drugs. Also HCQ is relatively safe except for common adverse effects such as gastrointestinal discomfort and pruritus. In this context hydroxychloroquine (HCQ) holds promise as a new drug. With extensive literature search till date there were no systematic reviews on antidiabetic efficacy of HCQ. Considering all these facts the present review was undertaken.

METHODS

This systematic review was aimed at reviewing the evidence on the antidiabetic efficacy of HCQ.

Criteria for selection of studies

Randomised controlled trials (RCTs) and cohort studies were included in this review. Population included those with or at risk of type 2 diabetes mellitus. Studies compared hydroxychloroquine with another drug or no drug. Outcomes measured were incidence of type 2 diabetes mellitus, HbA1C, Insulin Sensitivity Index (ISI), Homeostatic Model for Assessment of Insulin resistance (HOMA-IR), LDL-C and HDL-C.

Search methods for identifying the studies

Electronic search was carried out using the keywords- hydroxychloroquine, type 2 diabetes mellitus (T2DM). MEDLINE database was searched for studies. All the studies satisfying the inclusion criteria were considered for the review. The references of all the studies identified were inspected for more studies (Figure 1).

Data collection and analysis

Two authors independently read the full texts of the articles obtained and decided on the inclusion for review. A data extraction form was developed and used to extract all the relevant characteristics and outcome measurements from the studies. Both authors independently carried out the data extraction and recorded the data in the data extraction form. Any disagreements were settled by consensus.

Figure 1: Flowchart of literature search and selection.

Risk of bias in the RCTs that were available as full texts was assessed by using Cochrane risk of bias tool. Diversity in the RCTs and cohort studies with respect the population studied, interventions/exposures and the outcomes measured made meta-analysis impractical.

RESULTS

Description of the included studies

Three RCTs were included for the review. 425 adults studied. Two studies compared HCQ with pioglitazone/placebo in uncontrolled diabetes mellitus. One study compared HCQ with placebo in non-diabetics with rheumatoid arthritis (RA) (Table 1, Table 2, Table 3).

Table 1: RCT 1.

<table>
<thead>
<tr>
<th>Authors</th>
<th>N</th>
<th>Population</th>
<th>Intervention</th>
<th>Outcome</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pareek A et al</td>
<td>267</td>
<td>uncontrolled T2DM HbA1c 7.5-11.5 On SU+MF</td>
<td>HCQ 400mg/d Vs. Pioglitazone 15mg/d (for 24 weeks)</td>
<td>HbA1c (%)</td>
<td>-0.87 vs -0.9 (p &gt; 0.05)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FBS (mg/dl)</td>
<td>-14.2 vs -18.3 (p &gt; 0.05)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PPBS</td>
<td>-31.8 vs -24.5 (p &gt; 0.05)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TC</td>
<td>-14.3 vs -1.16 (p &lt;0.05)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>LDL</td>
<td>-8.89 vs +3.4 (p &lt;0.05)</td>
</tr>
</tbody>
</table>

Risk of bias Couldn’t be assessed


Four cohort studies were considered for review. Two studies involving 12,723 rheumatologic disease patients compared the incidence of T2DM in those who received HCQ with those who didn’t. One study compared methotrexate with HCQ in diabetics with rheumatologic diagnosis. Another study assessed the effect of HCQ on glycaemic and lipid parameters in obese non-diabetics (Table 4, Table 5, Table 6, Table 7).
Table 2: RCT 2.

<table>
<thead>
<tr>
<th>Authors</th>
<th>N</th>
<th>Population</th>
<th>Intervention</th>
<th>Outcome</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solomon DH et al</td>
<td>23</td>
<td>adults with RA without DM</td>
<td>HCQ (6.5mg/kg/d) vs. placebo (8+8 weeks cross over trial)</td>
<td>ISI</td>
<td>+0.4 vs +0.14</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HOMA-IR</td>
<td>-0.3 vs -0.42</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HOMA-B</td>
<td>-5.8 vs -6.8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TC</td>
<td>-12.7 vs -3.0 (p &lt;0.05)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>LDL</td>
<td>-12.4 vs -4.2 (p &lt;0.05)</td>
</tr>
</tbody>
</table>

Risk of bias

Computer generated random sequence

Allocation not concealed

 double blind

Outcomes- ADRs not reported in detail

Conflict of interest declared

RA- Rheumatoid Arthritis, HCQ- Hydroxychloroquine, ISI- Insulin Sensitivity Index, HOMA-IR- Homeostatic Model Assessment of Insulin Resistance, HOMA-B- Homeostatic Model Assessment of Beta cell function. +, plus sign indicates increase and -, minus sign indicates reduction in the parameters.

Table 3: RCT 3.

<table>
<thead>
<tr>
<th>Authors</th>
<th>N</th>
<th>Population</th>
<th>Intervention</th>
<th>Outcome</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gerstein HC et al</td>
<td>135</td>
<td>35-80 yrs, BMI &gt;25, Hba1c &gt;11% SU resistant</td>
<td>HCQ (max 600mg/d) vs. placebo for 18 months</td>
<td>Withdrawal from study due to inadequate glycaemic control.</td>
<td>69.6% vs 95.5%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hba1c*</td>
<td>-0.96% (vs placebo) (95% CI -0.24 to -1.81)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TC*</td>
<td>-13.92 mg/dl (p&lt;0.05)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>LDL*</td>
<td>-16.63 mg/dl (p&lt;0.05)</td>
</tr>
</tbody>
</table>

Risk of bias

Computer generated random sequence

Allocation not concealed

Double blind

Nil incomplete outcomes or selective reporting, ADRs reported

Conflict of interest not declared

*Values in low HbA1c (11%-13.4%) stratum at 9 months, HCQ- Hydroxychloroquine, BMI- Body Mass Index, HbA1c- Glycated haemoglobin, FBS- Fasting Blood Sugar, PPBS- Postprandial Blood Sugar, TC- Total Cholesterol, LDL- Low Density Lipoprotein. ‘-’, negative sign indicates reduction.

Table 4: Cohort 1.

<table>
<thead>
<tr>
<th>Authors</th>
<th>N</th>
<th>Population</th>
<th>Exposure</th>
<th>Outcome</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chen YM et al, 2015</td>
<td>8628</td>
<td>HCQ users, ≤129g- 5556 (vs), &lt;129g- 1871</td>
<td>Cumulative HCQ dose ≥129g vs &lt;129g. Mean follow up 5.6 yrs.</td>
<td>incidence of DM</td>
<td>HR=0.26 for patients taking ≥129g HCQ</td>
</tr>
</tbody>
</table>


Table 5: Cohort 2.

<table>
<thead>
<tr>
<th>Authors</th>
<th>N</th>
<th>Population</th>
<th>Exposure</th>
<th>Outcome</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mercer E et al</td>
<td>13</td>
<td>obese adults without DM, BMI &gt;30</td>
<td>HCQ 6.5mg/ kg/ day for 6 weeks</td>
<td>ISI, HOMA-IR, TC, LDL.</td>
<td>ISL: +4.5 (p=0.04), HOMA-IR: -0.3(p=0.09), TC: -7 mg/dl (p=0.05), LDL: -6 mg/dl (p&lt;0.05)</td>
</tr>
</tbody>
</table>

HCQ- Hydroxychloroquine, RA- Rheumatoid Arthritis, ISI- Insulin Sensitivity Index, HOMA-IR- Homeostatic Model Assessment of Insulin Resistance, TC- Total Cholesterol, LDL- Low Density Lipoprotein. ‘-’, negative sign indicates reduction and +, plus sign. Indicates increase

Risk of bias assessment

Two RCTs by Gerstein H C et al and Solomon D H et al were assessed for the risk of bias. There was high risk of selection bias in both the trials because of no mention of allocation concealment. High risk of reporting bias in the former and undeclared conflict of interest in the latter study was observed. There was low risk of bias in random sequence generation, blinding of participant/assessors.

<table>
<thead>
<tr>
<th>Authors</th>
<th>Year</th>
<th>N</th>
<th>Population</th>
<th>Exposure</th>
<th>Outcome</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rekedal LR et al</td>
<td>2007</td>
<td>4095</td>
<td>age &gt;16, Rheumatologic diagnosis</td>
<td>HCQ vs no HCQ</td>
<td>incidence of DM</td>
<td>5.2 vs 8.9 per 1000 pt yrs. (p≤0.001)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RR=0.23 for HCQ use &gt;4 yrs</td>
</tr>
</tbody>
</table>

**DISCUSSION**

Diabetes mellitus with a global prevalence of 8.6% is an important public health problem with long term complications like renal failure, blindness and coronary artery disease. The macrovascular and microvascular complications contribute to the morbidity and mortality due to diabetes mellitus. According to the A1cJieve study, the prevalence of complications in Indian population with type 2 diabetes mellitus were as follows-cardiovascular (23.6%), neuropathy (24.6%), nephropathy (21.1%), retinopathy (16.6%), foot ulcers (5.1%).

The United Kingdom Prospective Diabetes study (UKPDS) showed that oral anti-diabetic drugs/ insulin (vs. diet alone) significantly reduce complications like retinopathy, nephropathy, and neuropathy. Each percentage point reduction in glycated haemoglobin reduced the risk of these complications by 35%. Given the importance of diabetes as a global health problem, efforts to identify treatments that can manage this disorder have gained priority. Oral antidiabetic therapy is still incomplete.

Many below discussed studies have shown that antimalarials such as hydroxychloroquine, a long-standing safe and inexpensive treatment for autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, improve glucose tolerance and prevent diabetes mellitus with novel mechanism of action. So HCQ can be considered as a potential agent for the treatment of type 2 diabetes mellitus in general population. This is the first systematic review on antidiabetic efficacy of HCQ. The available studies were widely diverse not permitting meta-analysis. Hence each study was individually summarized.

Pareek A et al found HCQ to be as efficacious as pioglitazone in reducing glycaemic parameters (p >0.05) and also superior to it in improving lipid parameters (p<0.05) in a 24 week RCT on diabetic patients. Another RCT by Gerstein et al on 135 patients with T2DM resistant to sulfonylureas showed significant reduction of HbA1c (-0.96%) with 18 months of HCQ without significant improvement in insulin resistance. This study supported the hypothesis of reduced insulin degradation as the possible mechanism of action of HCQ. A 16 weeks cross over RCT on 23 RA patients without T2DM by Solomon DH et al showed that 8 weeks of HCQ significantly reduced Total and LDL cholesterol (p<0.05) but had no effect on insulin resistance parameters. Moreover HCQ is relatively safe and well tolerated. A study by Mercer E et al on 13 obese non-diabetics showed significant improvement in insulin resistance with 6 weeks of HCQ. No concurrent evidence of improvement in inflammatory markers was observed (for example, CRP and IL-6 did not change). This argues for a direct effect of HCQ on insulin metabolism-reduced degradation or enhanced activity at the receptor level rather than an indirect effect through reduced inflammation. Another study by Quatraro et al showed decreased insulin requirements in diabetic patients receiving HCQ with the C peptide levels remaining the same. Inhibitory effect on insulin metabolism in animal models and in vitro studies have also been documented with evidence of decreased degradation and intracellular accumulation.

Chloroquine analogues have plasma lipid-lowering effects in diabetes mellitus, RA, SLE and dyslipidaemia that are therapeutically relevant due to the increased risks of premature atherosclerosis in these diseases. Mechanisms responsible for altered lipid profiles with chloroquine analogue treatment include a significant

<table>
<thead>
<tr>
<th>Authors</th>
<th>Year</th>
<th>N</th>
<th>Population</th>
<th>Exposure</th>
<th>Outcome</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wasko MCM et al</td>
<td>2007</td>
<td>82</td>
<td>Rheumatic patients with diabetes</td>
<td>HCQ vs MTX</td>
<td>HbA1c measured at baseline and again within 12 months</td>
<td>-0.66% vs. -0.11%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>45</td>
<td>HCQ=45, MTX=37</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 6: Cohort 3.

Table 7: Cohort 4.
increase in lipid clearance rate and up-regulation of LDL receptors. In this context chloroquine is effective as both hypolipidaemic and antidiabetic drug.

In rheumatic disease patients, systemic inflammation appears to be responsible for insulin resistance through elevated levels of TNFα and IL-6. The glycaemic improvement afforded by HCQ is seen in diabetics as well as in rheumatologic disease patients indicating a mechanism other than suppression of inflammation. In addition HCQ was superior to methotrexate in reducing the HbA1c (-0.66% vs 0.11%) among RA patients in a retrospective cohort study again highlighting a mechanism other than anti-inflammatory action.

Two cohort studies by Chen YM et al and Wasko M et al found reduced risk of developing T2DM in patients with rheumatologic diseases in hydroxychloroquine users compared with nonusers. Risk reduction was proportional to dose and duration of HCQ administration. Risk is decreased by 74%-77% with ≥129 g cumulative dose of HCQ and/ or 4 years of HCQ use. HCQ is the least toxic of the 4 amino quinolines, and perhaps the least toxic of DMARDS. Patients given HCQ do not need any specific laboratory monitoring but do need periodic ophthalmic checks for early signs of reversible retinal toxicity. HCQ is relatively safe except for the rare adverse effects like retinopathy, neuromyopathy, and myopathy. Most common adverse effects are gastrointestinal discomfort and pruritus. Other side effects include nausea, epigastric pain, myopathy, haemolytic anaemia and skin pigmentation. So it has been suggested that formulations of HCQ containing S-enantiomer may reduce the risk of retinopathy and skin pigmentation.

Because of the antidiabetic efficacy, relative safety and low cost of hydroxychloroquine, it emerges as a therapeutic option for type 2 diabetic mellitus. With further good quality RCTs, a more useful and precise result can be obtained from systematic reviews and meta-analysis.

CONCLUSION

HCQ is comparable with pioglitazone in improving glycaemic control in T2DM. Reduced incidence of T2DM is seen in HCQ treated RA and SLE patients. In addition trials have consistently shown significant reduction in total cholesterol and LDL-cholesterol levels. Further studies on the mechanism and efficacy of different doses of this drug in patients with diabetes who are on different therapeutic regimens, with different degrees of hyperglycemia are clearly needed to include HCQ in therapeutic armamentarium of type 2 diabetes mellitus.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** The study was approved by the Institutional Ethics Committee

**REFERENCES**


